Synthesis, characterization, and immunologic properties of detoxified lipooligosaccharide from nontypeable Haemophilus influenzae conjugated to proteins.
Nontypeable Haemophilus influenzae (NTHi) is an important cause of otitis media in children and of pneumonitis in adults with depressed resistance. Lipooligosaccharide (LOS) is a major surface antigen of NTHi and elicits bactericidal and opsonic antibodies. We prepared detoxified LOS (dLOS) protein conjugates from NTHi for use as experimental vaccines. LOS from NTHi 9274 was treated with anhydrous hydrazine and had its toxicity reduced to clinically acceptable levels. dLOS was bound to tetanus toxoid (TT) or high- molecular-weight proteins (HMPs) from NTHi through a linker of adipic acid dihydrazide to form dLOS-TT or dLOS-HMP. The molar ratio of the dLOS to protein carriers ranged from 26:1 to 50:1. The antigenicity of the conjugates was similar to that of the LOS alone as determined by double immunodiffusion. Subcutaneous or intramuscular injection of the conjugates elicited a 28- to 486-fold rise in the level of immunoglobulin G antibodies in mice to the homologous LOS after two or three injections and a 169- to 243-fold rise in the level of immunoglobulin G antibodies in rabbits after two injections. The immunogenicity of the conjugates in mice and rabbits was enhanced by formulation with monophosphoryl lipid A plus trehalose dimycolate. In rabbits, conjugate-induced LOS antibodies induced complement-mediated bactericidal activity against the homologous strain 9274 and prototype strain 3189. These results indicate that a detoxified LOS-protein conjugate is a candidate vaccine for otitis media and pneumonitis caused by NTHi.
Gu
X X
XX
Vaccine Development Unit, Laboratory of Cellular Biology, National Institute of Deafness and Other Communication Disorders, NIH, Rockville, Maryland 20850, USA. xgu@pop.nidcd.nih.gov
Tsai
C M
CM
Ueyama
T
T
Barenkamp
S J
SJ
Robbins
J B
JB
Lim
D J
DJ
D000818:Animals; D005260:Female; D006193:Haemophilus influenzae / Q000276:immunology*; D006801:Humans; D007106:Immune Sera / Q000276:immunology; D007252:Influenza Vaccines / Q000276:immunology*; D008070:Lipopolysaccharides / Q000096:biosynthesis / Q000276:immunology*; D051379:Mice; D008970:Molecular Weight; D011817:Rabbits; D013745:Tetanus Toxoid / Q000276:immunology; D018074:Vaccines, Conjugate / Q000276:immunology; D014614:Vaccines, Synthetic / Q000276:immunology*
D007106:Immune Sera; D007252:Influenza Vaccines; D008070:Lipopolysaccharides; D013745:Tetanus Toxoid; D018074:Vaccines, Conjugate; D014614:Vaccines, Synthetic; C023023:lipid-linked oligosaccharides